FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20040	

OMB APPROVAL						
OMB Number:	3235-028					
Estimated average burden						

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

`,			or Section 30(h) of the Investment Company Act of 1940	·
1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol FIBROGEN INC [FGEN]	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner
(Last) C/O FIBROGE 409 ILLINOIS		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/20/2018	X Officer (give title Other (specify below) Chief Executive Officer
(Street) SAN FRANCISCO (City)	CA (State)	94158 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I. New Devivative Conviction Associated Dispensed of an Developelly Owned

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	03/20/2018		M		9,042	A	\$3.6	2,969,251	D	
Common Stock	03/20/2018		S		14,932(1)	D	\$50.64(2)	2,954,319	D	
Common Stock	03/20/2018		S		3,968(1)	D	\$51.02(3)	2,950,351	D	
Common Stock	03/20/2018		s		918(1)	D	\$50.71(4)	119,580	I	By Family Partnership
Common Stock	03/21/2018		M		9,042	A	\$3.6	2,959,393	D	
Common Stock	03/21/2018		S		18,000(1)	D	\$51.17 ⁽⁵⁾	2,941,393	D	
Common Stock	03/21/2018		S		900(1)	D	\$51.63 ⁽⁶⁾	2,940,493	D	
Common Stock	03/21/2018		S		918(1)	D	\$51.13 ⁽⁷⁾	118,662	D	
Common Stock								19,500	I	By Spouse
Common Stock								60,946	I	See footnote ⁽⁸⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3A. Deemed 5. Number 6. Date Exercisable and 7. Title and 9. Number of 11. Nature 3. Transaction 8. Price of 10. Expiration Date (Month/Day/Year) Amount of Securities Derivative Conversion **Execution Date** Transaction Derivative derivative Ownership of Indirect Security (Instr. 3) or Exercise (Month/Day/Year) Code (Instr. Derivative Security Securities Beneficial if any Form: (Month/Day/Year) Direct (D) Price of 8) Securities Underlying (Instr. 5) Beneficially Ownership Acquired (Instr. 4) (A) or Disposed of (D) Security (Instr. 3 and 4) Following (I) (Instr. 4) Reported Transaction(s) (Instr. 3, 4 and 5) (Instr. 4) Amount Number of Shares Expiration (D) Title Code (A) Exercisable Date Stock Option Common (9) \$3.6 03/20/2018 M 9,042 03/11/2019 9.042 \$0.00 463,103 D (Right to Stock Buy) Stock Option Common (9) 03/21/2018 9,042 03/11/2019 9.042 454,061 \$3.6 M \$0.00 D (Right to Stock

Explanation of Responses:

Buv)

- 1. Shares sold pursuant to a 10b5-1 plan.
- 2. The shares were sold at prices ranging from \$50.10 to \$50.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. The shares were sold at prices ranging from \$51.00 to \$51.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 4. The shares were sold at prices ranging from \$50.20 to \$50.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 5. The shares were sold at prices ranging from \$50.575 to \$51.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

- 6. The shares were sold at prices ranging from \$51.60 to \$51.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 7. The shares were sold at prices ranging from \$50.65 to \$51.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 8. The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.

9. Fully vested.

Remarks:

/s/ Dorothy Pacini, Attorneyin-fact 03/22/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.